For immediate release: June 3, 2019
Boston, MA – Buprenorphine-naloxone (buprenorphine), a highly effective, evidence-based treatment for opioid use disorder (OUD), is difficult to access in states with high rates of death associated with OUD, according to new research led by Harvard T.H. Chan School of Public Health. The study also found that access to buprenorphine is especially challenging among patients with Medicaid coverage.
“We were surprised to find roadblocks at every step of the process of getting buprenorphine, from finding a clinic with any prescribed, to finding one that will take public insurance,” said Michael Barnett, assistant professor of health policy and management at Harvard Chan School.
The findings will be published online June 3, 2019 in the Annals of Internal Medicine.
Improving treatment for OUD is a national priority. Use of buprenorphine, which can be prescribed in office-based setting and outpatient settings, has been associated with substantial reductions in opioid overdose deaths and a greater likelihood of successful long-term recovery among OUD patients. However, numerous barriers limit access to this treatment option.
For this study, Harvard Chan researchers and colleagues at Harvard Medical School and Johns Hopkins Bloomberg School of Public Health wanted to assess real-world access to buprenorphine among uninsured and Medicaid-covered patients. To do so, they created an audit survey, also known as a “secret shopper study,” in which each health care provider was called twice, once by a caller posing as a Medicaid enrollee and once as an uninsured patient. The calls were limited to providers in six areas of the U.S. that have high burdens of OUD, including Massachusetts, Maryland, New Hampshire, West Virginia, Ohio, and Washington, D.C.
Overall, there were 1,092 “patient” contacts with 546 buprenorphine prescribers. The findings showed that 38% to 46% of callers who reported current heroin use were denied an appointment, which the authors said may represent a substantial barrier for patients who are hoping to access care rapidly. The study also found that only 50% to 66% of clinicians booking a new appointment allowed buprenorphine to be prescribed on the first visit. Additionally, a smaller percentage of callers with Medicaid coverage than those paying with cash were offered appointments.
The researchers said that the scarcity of clinicians accepting new patients is a prominent barrier to care. However, among clinicians that were accepting patients, wait times were generally less than two weeks, indicating that there are opportunities to improve access to buprenorphine.
“Wait times were much shorter than we expected. We think this implies that interventions to increase awareness of available prescribers could provide a short-term boost for access to addiction treatment,” said Barnett.
Other Harvard Chan School researchers include Tamara Beetham and Marema Gaye.
Funding for this study came from National Institute on Drug Abuse.
“Rates of Opioid-Related Mortality,” Tamara Beetham, Brendan Saloner, Sarah E. Wakeman, Marema Gaye, and Michael L. Barnett, Annals of Internal Medicine, online June 3, 2019, doi: 10.7326/M18-3457
For more information:
Harvard T.H. Chan School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere. As a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory to people’s lives—not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices. Each year, more than 400 faculty members at Harvard Chan School teach 1,000-plus full-time students from around the world and train thousands more through online and executive education courses. Founded in 1913 as the Harvard-MIT School of Health Officers, the School is recognized as America’s oldest professional training program in public health.